Project Grant R42AI177202
Award Date
5/1/23
Completion Date
4/30/24
Dollars Obligated
$1.9M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Thyreos Inc. (GFGNCMZKKLF7)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on developing a potentially curative gene editing therapy for latent Herpes Simplex Virus Type 2 (HSV-2) infection. The $303,731 award to Caladan Therapeutics, Inc. aims to select and validate a lead meganuclease variant that can specifically target and eliminate HSV-2 from latently infected ganglionic neurons, which...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $841,397 to develop a multi-compartment intravaginal ring (IVR) for the prevention of genital herpes and unintended pregnancy. The key products and services being delivered under this grant include: Evaluating a panel of small-molecule inhibitors of soluble adenylyl cyclase (SAC) to select a lead candidate for...
The U.S. Defense Health Agency awarded a $1,753,267.00 Project Grant to Vaxsyna, Inc., a small disadvantaged, woman-owned business, to develop a plant-made vaccine for the prevention of Herpes Simplex Virus (HSV). This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform healthcare for the U.S. military and the public. The grant's period of performance is from August 1, 2023, to July 31, 2027, indicating a...
This Project Grant award, valued at $215,810 and funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the mechanisms by which the herpes simplex virus type 1 (HSV-1) degrades host proteins in neurons to enable viral replication and reactivation from latency. The primary awardee, the University of Virginia, will collaborate with the University of Cambridge to: 1)...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $236,292 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Tufts University School of Medicine to capture and characterize the structural complexes of the herpes simplex virus (HSV) glycoproteins critical for viral entry. The project aims to use new methods to isolate and analyze the 3D structures of the GD/GH/GL and GH/GL/GB glycoprotein complexes involved in HSV cell entry, which have been...
This $59,956,646 Cooperative Agreement, awarded on August 27, 2024 by the National Institutes of Health (NIH) under the Advanced Research Projects Agency for Health (ARPA-H) program (CFDA 93.384), funds the development of universal vaccine design approaches for herpesviruses. The project aims to apply innovative AI-based computational methods to design stabilized antigens and protein nanoparticle vaccines that can broadly protect against human herpesviruses like HSV-1, HSV-2, and EBV. The...
This $881,878 federal Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award aims to study the cross-talk between skin-resident T-cells (CD8 T resident memory cells) and keratinocytes, the primary target of herpes simplex virus (HSV) infection, to understand how this interaction influences HSV recurrence. The research will utilize advanced techniques such as single-cell RNA...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,486,800.00 to the Albert Einstein College of Medicine to conduct research on the role of TNFRSF14 signaling in promoting antibody-dependent cell-mediated cytotoxicity (ADCC) for herpes simplex virus (HSV) vaccine development. The project aims to identify the signaling pathways and structural determinants that...
This federal Project Grant award of $651,832 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate how the herpes simplex virus (HSV-1) manipulates the host cell's DNA damage response and proteome to promote viral gene expression and replication. The research team at The Children's Hospital of Philadelphia will use multi-modal proteomics techniques to define how changes to...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop and evaluate a novel multi-epitope protease cleavage sites (MEPCS) vaccine for protecting against SIV (Simian Immunodeficiency Virus) rectal transmission. The $650,156 award, effective August 21, 2024 through June 30, 2029, will support comparative evaluations of a cold-chain friendly and long-term stable...